- Home
- OBE vs KMDA Comparison
OBE vs KMDA Comparison
Compare OBE & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBE
- KMDA
- Stock Information
- Founded
- OBE 1979
- KMDA 1990
- Country
- OBE Canada
- KMDA Israel
- Employees
- OBE N/A
- KMDA N/A
- Industry
- OBE Oil & Gas Production
- KMDA Biotechnology: Pharmaceutical Preparations
- Sector
- OBE Energy
- KMDA Health Care
- Exchange
- OBE Nasdaq
- KMDA Nasdaq
- Market Cap
- OBE 402.1M
- KMDA 442.1M
- IPO Year
- OBE N/A
- KMDA N/A
- Fundamental
- Price
- OBE $6.01
- KMDA $7.46
- Analyst Decision
- OBE Strong Buy
- KMDA Strong Buy
- Analyst Count
- OBE 1
- KMDA 2
- Target Price
- OBE $14.00
- KMDA $14.50
- AVG Volume (30 Days)
- OBE 486.6K
- KMDA 346.0K
- Earning Date
- OBE 02-25-2025
- KMDA 03-05-2025
- Dividend Yield
- OBE N/A
- KMDA N/A
- EPS Growth
- OBE N/A
- KMDA 124.29
- EPS
- OBE 1.05
- KMDA 0.27
- Revenue
- OBE $516,155,298.00
- KMDA $158,380,000.00
- Revenue This Year
- OBE $23.37
- KMDA $15.37
- Revenue Next Year
- OBE $5.83
- KMDA $8.58
- P/E Ratio
- OBE $5.19
- KMDA $28.13
- Revenue Growth
- OBE 3.06
- KMDA 4.52
- 52 Week Low
- OBE $4.87
- KMDA $4.74
- 52 Week High
- OBE $9.07
- KMDA $9.15
- Technical
- Relative Strength Index (RSI)
- OBE 63.68
- KMDA 52.89
- Support Level
- OBE $5.25
- KMDA $7.51
- Resistance Level
- OBE $6.18
- KMDA $8.35
- Average True Range (ATR)
- OBE 0.24
- KMDA 0.41
- MACD
- OBE 0.09
- KMDA -0.02
- Stochastic Oscillator
- OBE 85.54
- KMDA 33.20
About OBE Obsidian Energy Ltd.
Obsidian Energy Ltd is an intermediate-sized oil and gas producer with strategic assets in Alberta. It operates in a single reporting segment that is exploration, development, and holding an interest in oil and natural gas properties and related production infrastructure in the Western Canada Sedimentary Basin. The company generates the majority of the revenue from the Crude oil sale.
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.